全球幽門螺旋桿菌（H. pylori）非侵入性檢測市場規模（按檢測類型、最終用戶、地區、範圍和預測）

非侵入性幽門螺旋桿菌（H. pylori）檢測市場規模的變化及預測

2024 年幽門螺旋桿菌 (H. pylori) 非侵入性檢測市場規模價值 6.903 億美元，預計到 2032 年將達到 9.3082 億美元，2026 年至 2032 年的複合年成長率為 4.20%。

非侵入性幽門螺旋桿菌 (H. pylori) 檢測包括尿素呼氣試驗、糞便抗原檢測和血清學檢測，這些檢測無需內視鏡檢查即可診斷病菌感染。尿素呼吸檢測需要攝取一種碳同位素標記的尿素溶液（此尿素溶液可被幽門螺旋桿菌代謝），並檢測呼氣中的二氧化碳。糞便抗原檢測可檢測糞便中的 H. pylori 蛋白，而血清學檢測可檢測血液中的 H. pylori 抗體。

這些檢測對於確定幽門螺旋桿菌病菌感染至關重要，幽門螺旋桿菌感染是消化性潰瘍和胃癌的主要原因。這些檢測提供了一種便捷、患者友善的治療方法，可以取代內視鏡切片檢查等侵入性治療。非侵入性檢測對於早期診斷、治療後監測以及篩檢幽門螺旋桿菌相關疾病風險族群至關重要。

非侵入性檢測的進步旨在提高準確性、降低成本並增加可及性。分子診斷和即時診斷等新技術將徹底改變幽門螺旋桿菌的檢測方式，從而實現廣泛的篩檢和早期療育。個人化醫療方法也可能包括非侵入性診斷，以調整治療策略，從而減輕全球幽門螺旋桿菌相關疾病的負擔。

幽門螺旋桿菌（H. pylori）非侵入性檢測的全球市場動態

關鍵市場促進因素

病菌感染不斷上升：全球病菌感染不斷上升，尤其是在開發中國家，這推動了對非侵入性檢測的需求。人們認知到與幽門螺旋桿菌相關的健康危害，例如消化性潰瘍和胃癌，這凸顯了快速便捷的診斷工具的重要性。

非侵入性診斷的偏好：尿素呼氣試驗、糞便抗原檢測和血清學檢測等非侵入性檢測相比侵入性治療具有許多優勢，包括提高患者舒適度、降低併發症風險以及易於操作。這些偏好推動了非侵入性診斷在臨床實務中的應用。

技術進步與創新：診斷技術的不斷開拓，包括開發更準確、更具成本效益和更快速的檢測方法，正在推動市場擴張。分子診斷和即時檢測的技術創新正在提高幽門螺旋桿菌診斷的效率和可及性，從而推動市場成長。

主要挑戰

準確性和可靠性擔憂：幽門螺旋桿菌的非侵入性診斷方法雖然便捷，但有時會出現假陽性或假陰性結果。尤其是血清學檢測，其準確性參差不齊，可能發現既往疾病而非當前疾病，這使得可靠的診斷和監測變得困難。

成本和可近性問題：儘管技術不斷發展，但某些非侵入性診斷方法（例如尿素呼氣試驗）的成本可能過高，難以廣泛應用，尤其是在低收入人群中。農村和服務欠缺地區難以獲得先進的實驗室和設備，阻礙了這些診斷方法的廣泛應用。

抗生素抗藥性：抗生素抗藥性的增加影響了病菌感染的治療。除了非侵入性檢測外，還必須進行抗生素敏感性測試以確保適當的治療，但這種測試很複雜，並且會增加診斷的成本和時間。

主要趨勢：

採用就地檢驗(POC)：市場正轉向照護現場診斷設備，這些設備可在患者所在位置提供快速且準確的結果。此類照護現場設備在初級基層醫療機構和偏遠地區尤其有用，因為它們提高了可近性，最大限度地減少了等待時間，並提高了患者的依從性。

先進分子診斷技術的整合：非侵入性幽門螺旋桿菌檢測擴大採用分子診斷技術，例如聚合酵素鏈鎖反應(PCR) 和次世代定序(NGS)。這些方法提高了靈敏度和特異性，從而能夠更準確地檢測和鑑定感染情況。

個人化醫療和標靶治療：個人化醫療的日益成長趨勢正在影響幽門螺旋桿菌檢測市場。目前正在開發的非侵入性檢測方法，可以檢測細菌的存在，並同時提供有關抗生素抗藥性模式的資訊。這些資訊有助於制定針對每位患者病情的個人化治療策略，從而改善治療效果並降低抗生素抗藥性的風險。

目錄

第1章 引言

• 市場定義
• 市場區隔
• 調查方法

第2章執行摘要

• 主要發現
• 市場概覽
• 市場亮點

第3章市場概述

• 市場規模和成長潛力
• 市場趨勢
• 市場促進因素
• 市場限制
• 市場機會
• 波特五力分析

4. 幽門螺旋桿菌（H. pylori）非侵入性檢測市場（依檢測類型分類）（診斷）

• 尿素呼氣試驗（UBT）
• 糞便抗原檢測（HpSA）
• 血清學檢測

5. 幽門螺旋桿菌（H. pylori）非侵入性檢測市場（依最終使用者）

• 醫院
• 診斷實驗室
• 診所

第6章區域分析

• 北美洲
• 美國
• 加拿大
• 墨西哥
• 歐洲
• 英國
• 德國
• 法國
• 義大利
• 亞太地區
• 中國
• 日本
• 印度
• 澳洲
• 拉丁美洲
• 巴西
• 阿根廷
• 智利
• 中東和非洲
• 南非
• 沙烏地阿拉伯
• 阿拉伯聯合大公國

第7章市場動態

• 市場促進因素
• 市場限制
• 市場機會
• COVID-19 市場影響

第8章 競爭態勢

• 主要企業
• 市場佔有率分析

第9章 公司簡介

• Abbott
• Biomerica, Inc.
• Certest Biotec SL
• CorisBioconcept SPRL
• DiaSorin SpA
• Exalenz Bioscience Ltd.
• Meridian Bioscience, Inc.
• Sekisui Diagnostics
• Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd.

第10章 市場展望與機會

• 新興技術
• 未來市場趨勢
• 投資機會

第11章 市場展望 附錄

• 簡稱列表
• 來源和參考文獻

Helicobacter Pylori (H. Pylori) Non-Invasive Testing Market Size And Forecast

Helicobacter Pylori (H. Pylori) Non-Invasive Testing Market size was valued at USD 690.3 Million in 2024 and is projected to reach USD 930.82 Million by 2032, growing at a CAGR of 4.20% from 2026 to 2032.

Helicobacter pylori (H. pylori) non-invasive testing includes urea breath tests, stool antigen tests and serology tests that diagnose H. pylori infection without the need for an endoscopy. The urea breath test involves consuming a urea solution labeled with a carbon isotope which H. pylori metabolizes resulting in detectable carbon dioxide in the breath. Stool antigen tests detect H. pylori proteins in feces whereas serology tests detect antibodies to H. pylori in the bloodstream.

These tests are critical in determining H. pylori infection which is a leading cause of peptic ulcers and stomach cancer. They provide a convenient and patient-friendly alternative to invasive treatments such as endoscopic biopsies. Non-invasive testing is critical for initial diagnosis, post-treatment monitoring and screening in populations at risk of H. pylori-related illnesses.

Non-invasive testing advancements are intended to improve accuracy, lower costs and increase accessibility. Emerging technologies such as molecular techniques and point-of-care diagnostics are set to transform H. pylori detection allowing for broad screening and early intervention. Personalized medicine approaches may also include non-invasive diagnostics to adapt treatment strategies lowering the worldwide burden of H. pylori-related disorders.

Global Helicobacter Pylori (H. Pylori) Non-invasive Testing Market Dynamics

The key market dynamics that are shaping the global helicobacter pylori (h. pylori) non-invasive testing market include:

Key Market Drivers:

Increased Prevalence of H. Pylori Infections: The rising global incidence of H. pylori infections particularly in developing nations is driving the demand for non-invasive testing. Recognizing the health hazards associated with H. pylori such as peptic ulcers and stomach cancer emphasizes the importance of quick and accessible diagnostic tools.

Preference for Non-Invasive Diagnostic Methods: Non-invasive examinations such as urea breath tests, stool antigen testing and serology tests provide several advantages over invasive treatments including increased patient comfort, a lower risk of complications and ease of administration. This preference promotes the use of non-invasive diagnostics in clinical settings.

Technological Advancements and Innovation: Constant developments in diagnostic technology such as the creation of more accurate, cost-effective and rapid testing methods drive market expansion. Innovations in molecular diagnostics and point-of-care testing improve the efficiency and accessibility of H. pylori diagnosis propelling market growth.

Key Challenges:

Accuracy and Reliability Concerns: Non-invasive diagnostics for H. pylori while handy, can occasionally provide false positives or negatives. Variations in test accuracy particularly with serology tests that may reveal past rather than current illnesses make it difficult to provide reliable diagnosis and surveillance.

Cost and Accessibility Issues: Despite technical developments, the cost of certain non-invasive diagnostics such as the urea breath test can be too expensive for broad use especially in low-income communities. Limited access to advanced testing facilities and equipment in rural and underserved areas impedes widespread use of these diagnostic approaches.

Antibiotic Resistance: The increasing prevalence of antibiotic resistance affects the treatment of H. pylori infections. Non-invasive tests must be supplemented by antibiotic susceptibility testing to ensure appropriate therapy which adds complexity and may increase the cost and duration of the diagnostic procedure.

Key Trends:

Adoption of Point-of-Care Testing: The market is shifting toward point-of-care (POC) diagnostic instruments that deliver quick and precise results at the patient's location. These point-of-care diagnostics improve accessibility, minimize wait times and increase patient compliance making them especially useful in primary care settings and remote places.

Integration of Advanced Molecular Diagnostics: In non-invasive H. pylori testing, molecular diagnostic technologies such as polymerase chain reaction (PCR) and next-generation sequencing (NGS) are increasingly being used. These approaches have improved sensitivity and specificity allowing for more precise detection and characterization of infections.

Personalized Medicine and Targeted Therapy: The expanding trend of personalized medicine is influencing the H. pylori testing market. Non-invasive assays are being developed to detect the presence of bacteria while simultaneously providing information about antibiotic resistance patterns. This information allows treatment strategies to be tailored to each individual patient's illness profile increasing treatment outcomes and lowering the risk of antibiotic resistance.

Global Helicobacter Pylori (H. Pylori) Non-invasive Testing Market Regional Analysis

Here is a more detailed regional analysis of the global Helicobacter pylori (H. pylori) non-invasive testing market:

North America:

According to Verified Market Research analyst, North America is expected to dominate the global Helicobacter pylori (H. pylori) non-invasive testing market.

The region's dominance is due to a number of major factors. The region's high healthcare expenditure ensures access to new diagnostic technologies and allows for the rapid adoption of innovative, non-invasive testing methods. Furthermore, favorable payment rules significantly reduce patient's out-of-pocket expenses making these tests more affordable and encouraging widespread adoption. The combination of robust healthcare infrastructure and strong financial incentives fosters market expansion.

Furthermore, North America has a large patient population with H. pylori infections which fuels demand for diagnostic testing. Awareness campaigns and public health initiatives also play an important role in promoting early detection and regular screening which helps grow the market. The region's emphasis on preventative healthcare combined with the high frequency of gastrointestinal illnesses associated with H. pylori highlights the vital need for dependable diagnostic solutions solidifying North America's dominance in the H. pylori non-invasive market.

Asia Pacific:

The Asia Pacific region is expected to become the fastest-growing market for H. pylori non-invasive testing market driven by rising infection rates. H. pylori infection rates are high in countries such as China, India and Japan necessitating appropriate diagnostic techniques to control and treat gastrointestinal problems. The increased incidence of H. pylori infections underscores the critical need for accessible and reliable diagnostic technologies which is driving market expansion in the region.

Growing healthcare infrastructure in Asia Pacific contributes greatly to this expansion. Investments in updating healthcare facilities and increasing access to innovative medical technologies are helping the region's diagnostic capacities. Governments and corporate entities are prioritizing healthcare advancements resulting in better-equipped hospitals and clinics which encourages the use of non-invasive H. pylori testing procedures.

The region's enormous population base creates a significant market opportunity for H. pylori non-invasive diagnostics. With Asia Pacific home to a sizable fraction of the world's population, there is an enormous potential need for diagnostic services. Furthermore, rising awareness of H. pylori-related health conditions as well as a growing middle class with better access to healthcare facilities are driving up demand for improved therapies. These factors combine to position the Asia Pacific region as a prominent player in the future growth of the H. pylori non-invasive testing market.

Global Helicobacter Pylori (H. Pylori) Non-invasive Testing Market: Segmentation Analysis

The Global Helicobacter Pylori (H. Pylori) Non-invasive Testing Market is segmented on the basis of Test Type, End User, and Geography.

Helicobacter Pylori (H. Pylori) Non-invasive Testing Market, By Test Type

• Urea Breath Test (UBT)
• Stool Antigen Test (HpSA)
• Serological Testing

Based on Test Type, the market is Urea Breath Test (UBT), Stool Antigen Test (HpSA) and Serological Testing. The Urea Breath Test (UBT) dominates the H. pylori non-invasive testing market due to its high accuracy, non-invasiveness and rapid findings. UBT is preferred because it can detect active infections more accurately and is less impacted by recent antibiotic or proton pump inhibitor usage than other tests. It is the most reliable and patient-friendly method for diagnosing H. pylori infections.

Helicobacter Pylori (H. Pylori) Non-invasive Testing Market, By End User

• Hospitals
• Diagnostic Labs
• Clinics

Based on End User, the market is divided into Hospitals, Diagnostic Labs and Clinics. Hospitals dominate the market for H. pylori non-invasive testing because of their modern diagnostic centers, extensive patient care and high patient volume. Hospitals are frequently the primary facilities for diagnosing and treating gastrointestinal illnesses including H. pylori infections. Their comprehensive diagnostic test suite along with integrated care and follow-up therapies guarantees that they will always be the go-to option for precise and effective H. pylori testing.

Helicobacter Pylori (H. Pylori) Non-invasive Testing Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World
• On the basis of Geography, the Global Helicobacter Pylori (H. Pylori) Non-invasive Testing Market is classified into North America, Europe, Asia Pacific and the Rest of the world. North America dominates the H. pylori non-invasive testing market owing to high healthcare spending, attractive reimbursement rules and a large patient population. In contrast, the Asia Pacific region is rapidly emerging as the fastest-growing market driven by rising infection rates, improved healthcare infrastructure and a large population base that requires advanced diagnostic solutions.

Key Players

• The Global Helicobacter Pylori (H. Pylori) Non-invasive Testing Market study report will provide valuable insight with an emphasis on the global market. The major players in the market are Abbott, Biomerica Inc., Certest Biotec S.L., CorisBioconcept SPRL, DiaSorin S.p.A., Meridian Bioscience Inc., Sekisui Diagnostics and Shenzhen Zhonghe Headway Bio-Sci & Tech Co. Ltd.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share and market ranking analysis of the above-mentioned players globally.

• Helicobacter Pylori (H. Pylori) Non-invasive Testing Market Recent Developments
• In March 2023, RedHill, a speciality biopharmaceutical company declared that it has settled all of its debt, including principal, interest, revenue interest, prepayment premiums and exit costs. This contains RedHill Biopharma Inc.'s (the company's U.S. subsidiary) Credit Agreement with HCR.
• In July 2023, Meridian Bioscience received FDA clearance for Premier HpSA Flex, a significant advancement in non-invasive H. pylori diagnostic testing solutions. This milestone strengthened the company's position in the non-invasive H. pylori testing market.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Helicobacter Pylori (H. Pylori) Non-Invasive Testing Market, By Test Type (Diagnostics)

• Urea Breath Test (UBT)
• Stool Antigen Test (HpSA)
• Serological Testing

5. Helicobacter Pylori (H. Pylori) Non-Invasive Testing Market, By End User

• Hospitals
• Diagnostic Labs
• Clinics

6. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

7. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

8. Competitive Landscape

• Key Players
• Market Share Analysis

9. Company Profiles

• Abbott
• Biomerica, Inc.
• Certest Biotec S.L.
• CorisBioconcept SPRL
• DiaSorin S.p.A.
• Exalenz Bioscience Ltd.
• Meridian Bioscience, Inc.
• Sekisui Diagnostics
• Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd.

10. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

11. Appendix

• List of Abbreviations
• Sources and References